Q1 2026 Psychedelic Drug Development Pipeline: Bullseye Charts By Watertime - February 19, 2026 4 Q1 2026 BULLSEYE CHARTS This resource is supported by Learn More UBC partners with biopharma to modernize evidence… Source RELATED ARTICLESMORE FROM AUTHOR Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT... Colorado’s Ibogaine Bill Could Be a Landmark — If It Respects the Plant’s Roots Joe Moore Psychedelics Today on Leadership, Integration, and the Psychedelic Landscape
